SynthesisFrontiers in pharmacology2022
Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Prescribing Biologic Immune-Modifying Therapies for Patients with a History of Cancer: A Cross-Specialty Review.Current oncology (Toronto, Ont.) · 2026Review
- Review
- A Clinical Nomogram for Predicting Early Response to Biologics in Pediatric Allergic Asthma with Comorbid Allergic Rhinitis.Journal of asthma and allergy · 2026Article
- Targeted biologic therapies and advanced drug delivery approaches in asthma management: a clinical perspective.Inflammopharmacology · 2025Review
- Article
- Severe Dry Cough Followed by Eosinophilia Without Pulmonary Infiltrates After Dupilumab Treatment in Patients with Severe Asthma: A Series of Five Cases.Journal of inflammation research · 2025Article
- Real-World and Patient-Reported Outcomes of Dupilumab and Other Biological Drugs for Chronic Obstructive Pulmonary Disease-A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- An Updated Reappraisal of Dupilumab in Children and Adolescents with Severe Asthma.Children (Basel, Switzerland) · 2024Review
- Biologic therapies for severe asthma with persistent type 2 inflammation.Australian prescriber · 2024Review
- Advances in the Relationship between Respiratory Viruses and Asthma.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.